Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118729 · ClinicalTrials.gov registry record · Phase 3
Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 380
- Enrollment target
NCT00118729 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 380 participants.
The verdict
NCT00118729, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 380 participants
- Enrollment target
Study Summary
Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. The focus of this study, seasonal allergic rhinitis (SAR), is one type of allergic rhinitis that is triggered by the pollen from trees, grasses, and weeds. Commonly referred to as "hay fever", it is characterized by sneezing, nasal congestion and pruritus, rhinorrhea, and pruritic, watery, red eyes. The purpose of this study is to evaluate the onset of action of an investigational nasal spray, GW685698X aqueous nasal spray, versus vehicle placebo nasal spray in the treatment of seasonal allergic rhinitis caused by ragweed following a single dose of treatment in controlled pollen concentrations in an allergen challenge chamber.
Interventions
- DRUG GW685698X Aqueous Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2005-04 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118729
The ClinicalTrials.gov registry entry for NCT00118729 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW685698X Aqueous Nasal Spray is the first listed.
NCT00118729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118729 about?
NCT00118729 is a clinical study titled "Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action". Allergic rhinitis is an inflammatory disorder of the upper airway that occurs following allergen exposure. The focus of this study, seasonal allergic rhinitis (SAR), is one type of allergic rhinitis that is triggered by the pollen from trees, grasses, and weeds. Commonly referred to as "hay fever", ...
What is the current status of trial NCT00118729?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 380 participants. The study started on 2005-04. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00118729?
The interventions under investigation include: GW685698X Aqueous Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT00118729?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.